Has the U.S. Pharma Industry valuation changed over the past few years?

Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 42.7x which is lower than its 3-year average PE of 54.7x. The 3-year average PS ratio of 5.1x is lower than the industry's current PS ratio of 6.0x.

Which industries have driven the changes within the U.S. Healthcare industry?

There are no additional sub-industries under this industry.

U.S. Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 16 Sep 2026	US$2.6t	US$437.6b	US$61.1b	15.5x	42.7x	6x
Fri, 14 Aug 2026	US$2.6t	US$437.4b	US$59.9b	16.6x	44.1x	6x
Sun, 12 Jul 2026	US$2.5t	US$425.2b	US$66.0b	14.9x	38.6x	6x
Tue, 09 Jun 2026	US$2.4t	US$424.1b	US$66.3b	15x	36.4x	5.7x
Thu, 07 May 2026	US$2.3t	US$423.7b	US$62.4b	16.7x	36.6x	5.4x
Sat, 04 Apr 2026	US$2.3t	US$405.9b	US$72.5b	16.4x	31.5x	5.6x
Mon, 02 Mar 2026	US$2.4t	US$405.9b	US$72.4b	20x	33.5x	6x
Wed, 28 Jan 2026	US$2.3t	US$404.7b	US$73.2b	20.2x	31.4x	5.7x
Fri, 26 Dec 2025	US$2.3t	US$402.8b	US$71.4b	19.9x	31.7x	5.6x
Sun, 23 Nov 2025	US$2.2t	US$402.7b	US$71.4b	19.9x	30.3x	5.4x
Tue, 21 Oct 2025	US$1.9t	US$389.2b	US$63.5b	18.6x	29.6x	4.8x
Thu, 18 Sep 2025	US$1.8t	US$387.9b	US$60.9b	18.7x	29.2x	4.6x
Sat, 16 Aug 2025	US$1.7t	US$387.8b	US$61.0b	18.9x	28.1x	4.4x
Mon, 14 Jul 2025	US$1.8t	US$382.7b	US$61.3b	18.1x	28.8x	4.6x
Wed, 11 Jun 2025	US$1.7t	US$382.7b	US$61.2b	18.2x	28.3x	4.5x
Fri, 09 May 2025	US$1.7t	US$383.0b	US$64.0b	16.7x	26.7x	4.5x
Sun, 06 Apr 2025	US$1.7t	US$379.9b	US$41.3b	16x	40.4x	4.4x
Tue, 04 Mar 2025	US$2.0t	US$381.1b	US$39.3b	16.8x	49.8x	5.1x
Thu, 30 Jan 2025	US$1.8t	US$370.2b	US$29.9b	19.6x	61.7x	5x
Sat, 28 Dec 2024	US$1.8t	US$369.4b	US$31.1b	16.9x	58.4x	4.9x
Mon, 25 Nov 2024	US$1.8t	US$373.8b	US$30.6b	20.5x	59.3x	4.8x
Wed, 23 Oct 2024	US$2.0t	US$365.3b	US$23.7b	18.2x	84.6x	5.5x
Fri, 20 Sep 2024	US$2.0t	US$364.2b	US$25.4b	19x	80.3x	5.6x
Sun, 18 Aug 2024	US$2.0t	US$362.1b	US$21.8b	17.3x	91.7x	5.5x
Tue, 16 Jul 2024	US$2.0t	US$357.7b	US$13.8b	15.9x	146.1x	5.7x
Thu, 13 Jun 2024	US$1.9t	US$358.3b	US$14.1b	15.8x	138.1x	5.4x
Sat, 11 May 2024	US$1.9t	US$358.2b	US$13.5b	18.5x	137.7x	5.2x
Mon, 08 Apr 2024	US$1.9t	US$355.2b	US$22.8b	24.7x	82.2x	5.3x
Wed, 06 Mar 2024	US$1.9t	US$355.3b	US$22.5b	23.4x	84.5x	5.3x
Fri, 02 Feb 2024	US$1.8t	US$353.0b	US$22.3b	32x	80.4x	5.1x
Sun, 31 Dec 2023	US$1.7t	US$375.2b	US$33.8b	31.9x	49.9x	4.5x
Tue, 28 Nov 2023	US$1.7t	US$375.1b	US$33.9b	26x	48.8x	4.4x
Thu, 26 Oct 2023	US$1.7t	US$382.7b	US$44.7b	14.9x	36.9x	4.3x
Sat, 23 Sep 2023	US$1.7t	US$381.8b	US$43.9b	19.9x	38.3x	4.4x


US Market	-1.64%
Healthcare	-0.72%
Pharma	-0.64%
Pharma	-0.64%

Company	Last Price	7D	1Y	Valuation
LLY Eli Lilly	US$1.14k	1.1% +US$10.9b	48.6%	PE37.9x
TEVA Teva Pharmaceutical Industries	US$39.25	6.1% +US$2.6b	n/a	PE64.8x
SEPN Septerna	US$38.86	4.0% +US$69.5m	169.1%	PS18.3x
HELP Cybin	US$13.12	5.9% +US$53.3m	117.2%	PB4x
JAZZ Jazz Pharmaceuticals	US$240.83	0.3% +US$49.3m	90.3%	PE16.6x

Announcement • Sep 15

Johnson & Johnson Announces New Results From Phase 2b COPERNICUS Study Evaluating RYBREVANT FASPRO Plus LAZCLUZE With Prophylactic Strategies

Johnson & Johnson announced new results from the Phase 2b COPERNICUS study evaluating how subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib), with less frequent dosing and prophylactic strategies, can improve the treatment experience for patients with previously untreated advanced non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations. Early results show consistently low rates across key treatment-related events and treatment discontinuation. COPERNICUS was designed to reflect everyday clinical practice, enrolling a racially and ethnically diverse patient population across both academic and community sites. The data were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) (Abstract #M012.09).RYBREVANT FASPRO dual-targets EGFR and mesenchymal-epithelial transition (MET), two key drivers of tumor growth and treatment resistance, while also engaging the immune system. It is approved across multiple EGFR-mutated advanced NSCLC treatment settings and, for eligible patients, offers once-monthly dosing following initial weekly dosing. In this analysis, 214 U.S. patients received the recently approved RYBREVANT FASPRO plus LAZCLUZE regimen with prophylactic strategies to reduce the risk of blood clots with oral anticoagulation and skin-related side effects with an enhanced, easy-to-use skin care regimen evaluated in the COCOON study.At a median follow-up of 8.3 months, the majority of adverse events were Grade 1 or 2, with no new safety signals observed. Only eight percent of patients discontinued treatment due to adverse events. Rash was reported in 25 percent of patients, while administration-related reactions (ARRs) and venous thromboembolism (VTE) were each reported in three percent. No patients discontinued due to ARRs, and one percent discontinued due to rash and VTE.These findings represent lower numerical rates than observed with intravenous RYBREVANT (amivantamab-vmjw) plus LAZCLUZE in the Phase 3 MARIPOSA study, where rash, ARRs and VTE during the first four months of treatment were reported in 55%, 55% and 23% of patients, respectively. MARIPOSA also demonstrated that patients with advanced EGFR-mutated advanced NSCLC treated with the first-line regimen lived longer than those treated with osimertinib, with a statistically significant overall survival benefit (hazard ratio [HR], 0.75; P=0.005).COPERNICUS is one of the largest global studies conducted in patients with EGFR-mutated NSCLC, with a target enrollment of 300 previously untreated patients. Of the population reported here, median age was 67 years, 22% were age 75 or older, 27% were Asian, 10% were African American and 10% were Hispanic/Latino. This study reflects Johnson & Johnson's continued focus on improving the treatment experience for people with cancer, including how treatments are delivered and managed in everyday care.

Announcement • Sep 02

Teva Pharmaceutical Industries Limited Announces Positive Topline Results from Phase 2A Study in Celiac Disease for Its Anti-Il-15 Antibody

Teva Pharmaceutical Industries Limited announced positive topline results from an ongoing Phase 2a study of TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, in adults with celiac disease. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8. TEV ‘408 was well-tolerated, with no safety signals observed to date. The ongoing randomized, placebo-controlled study enrolled 50 adult participants with celiac disease on a gluten-free diet (GFD) with minimal intestinal damage at baseline as measured by the villous height-to-crypt depth ratio (Vh:Cd =2.0) and symptoms. Two weeks after receiving a single dose of TEV ‘408, participants began a six-week daily gluten challenge (GC). The study assessed biopsy-based measures of intestinal damage and inflammation along with patient-reported symptoms. At week 8 (the end of the GC) TEV ‘408 showed statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo, as measured by the trial’s primary endpoint of Vh:Cd ratio with a least squares (LS) mean change from baseline of -0.43 compared with -0.88 for placebo (treatment difference of 0.45, 95% CI: (0.06, 0.84), p<0.05). TEV ‘408 was well-tolerated, with no safety signals observed to date. Royalty Pharma invested $500 million to accelerate the clinical development of TEV ‘408. If approved and launched, Teva will pay a milestone to Royalty Pharma and a royalty on worldwide net sales of TEV ‘408. Celiac disease is a serious autoimmune disease in which exposure to gluten triggers an immune response that damages the small intestine. It affects approximately 1% of the global population, or more than three million people in the U.S. alone, although many individuals remain undiagnosed. Celiac disease can cause chronic digestive symptoms, fatigue, nutrient deficiencies, and other health complications that can significantly impact daily life. There are currently no approved therapies for celiac disease. A strict gluten-free diet (GFD) remains the standard of care, yet even with careful adherence, patients may continue to experience symptoms, reduced quality of life, and ongoing intestinal inflammation or damage due to inadvertent gluten exposure. The limitations of current management approaches underscore the need for therapies that address the underlying drivers of disease and improve outcomes for patients.

U.S. Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Jazz Pharmaceuticals Acquires Actio Biosciences for $820 Million Adding Epilepsy Therapy Candidate

Lilly Reaches Agreement With QurCan to Advance Nucleic Acid Therapies for Nervous System Diseases

Johnson & Johnson Announces New Results From Phase 2b COPERNICUS Study Evaluating RYBREVANT FASPRO Plus LAZCLUZE With Prophylactic Strategies

Elanco Animal Health Incorporated to Report Q3, 2026 Results on Nov 06, 2026

Merck Completes Cidara Acquisition Bringing Phase III Flu Therapy Into Late-Stage Pipeline

Pfizer: Firing On All Cylinders

Co-Founder recently bought US$1.2m worth of stock

VTRS: Pipeline Reliance Will Likely Disappoint Elevated 2026 Expectations

Bristol Myers Squibb Reports Positive Phase 2 Data for Multiple Myeloma CAR T Therapy

Belite Bio On Track For A Potential Blockbuster Launch In 2027

Novartis Phase 3 Setback Leaves Royalty Pharma Investment Intact With Portfolio Target Reaffirmed

Teva Pharmaceutical Industries Limited Announces Positive Topline Results from Phase 2A Study in Celiac Disease for Its Anti-Il-15 Antibody

Insider notifies of intention to sell stock

Insufficient new directors

Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term

Regencell Bioscience Faces DOJ Investigation After May $20 Million Equity Raise and Heavy Losses